Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02135692




Registration number
NCT02135692
Ethics application status
Date submitted
8/05/2014
Date registered
12/05/2014
Date last updated
3/12/2019

Titles & IDs
Public title
A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects
Scientific title
A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects With a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial
Secondary ID [1] 0 0
2014-000314-54
Secondary ID [2] 0 0
201312
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Asthma 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Other interventions - Mepolizumab
Treatment: Drugs - SOC

Experimental: Mepolizumab 100 mg - All subjects will receive mepolizumab 100mg administered SC into the upper arm or thigh approximately every 4 weeks.


Other interventions: Mepolizumab
Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.

Treatment: Drugs: SOC
Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists
Intervention code [1] 0 0
Other interventions
Intervention code [2] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annualized Rate of On-treatment Exacerbations Per Year
Timepoint [1] 0 0
Baseline (Week 0) to Week 172
Primary outcome [2] 0 0
Number of Participants With Any On-treatment Adverse Event (AE) or On-treatment Serious AE (SAE)
Timepoint [2] 0 0
Baseline (Week 0) to Week 172
Secondary outcome [1] 0 0
Mean Change From Baseline in Asthma Control Questionnaire (ACQ)-5 On-treatment Score
Timepoint [1] 0 0
Baseline (Week 0) to Week 168
Secondary outcome [2] 0 0
Mean Change From Baseline in On-treatment Clinic Pre-bronchodilator FEV1
Timepoint [2] 0 0
Baseline (Week 0) to Week 168
Secondary outcome [3] 0 0
Number of Participants Withdrawn From the Study Due to Lack of Efficacy and Adverse Events
Timepoint [3] 0 0
Baseline (Week 0) to Week 172
Secondary outcome [4] 0 0
Number of Participants Hospitalized Due to Adverse Events Including Asthma Exacerbations
Timepoint [4] 0 0
Baseline (Week 0) to Week 172
Secondary outcome [5] 0 0
Number of Participants With AEs Including Both Systemic (Allergic and Non-allergic) and Local Site Reactions
Timepoint [5] 0 0
Baseline (Week 0) to Week 172
Secondary outcome [6] 0 0
Mean Change From Baseline in QT Interval Corrected by Bazett's Method (QTcB) and QT Interval Corrected by Fridericia's Method (QTcF) Values for 12-lead Electrocardiogram (ECG)
Timepoint [6] 0 0
Baseline (Week 0) to Week 172
Secondary outcome [7] 0 0
Number of Participants With Maximum Change From Baseline in QTcB and QTcF Interval for ECG Assessed at Any Time Post Baseline
Timepoint [7] 0 0
Baseline (Week 0) to Week 172
Secondary outcome [8] 0 0
Change From Baseline in Systolic Blood Pressure and Diastolic Blood Pressure
Timepoint [8] 0 0
Baseline (Week 0) to Week 168
Secondary outcome [9] 0 0
Change From Baseline in Pulse Rate
Timepoint [9] 0 0
Baseline (Week 0) to Week 168
Secondary outcome [10] 0 0
Number of Participants With Positive Anti-mepolizumab Binding Antibodies (ADA) and Neutralizing Antibodies (NAb)
Timepoint [10] 0 0
Baseline (Week 0) to Week 172
Secondary outcome [11] 0 0
Number of Participants With Potential Clinical Importance Values for Change From Baseline Relative to the Reference Range for Clinical Chemistry Parameters at Any Time Post-Baseline
Timepoint [11] 0 0
Baseline (Week 0) to Week 172
Secondary outcome [12] 0 0
Number of Participants With Potential Clinical Importance Values for Change From Baseline Relative to the Reference Range for Hematology Parameters at Any Time Post-Baseline
Timepoint [12] 0 0
Baseline (Week 0) to Week 172

Eligibility
Key inclusion criteria
- Informed Consent: Prior to commencing any study related activities, subjects must be
able and willing to provide written informed consent.

- Male or Eligible Female Subjects: To be eligible for the study, females of
child-bearing potential must commit to consistent and correct use of an acceptable
method of birth control and for 4 months after the last study drug administration. A
urine pregnancy test is required of all females of childbearing potential at the
initial Baseline Visit (Visit 1).

- French Subjects Only: In France, a subject will be eligible for inclusion in this
study only if either affiliated to or a beneficiary of a social security category.

- MEA115661 Participation: Subjects must have completed Visit 14 of MEA115661.

- Current Anti-Asthma Therapy: The subject's asthma has been treated with an ICS
controller medication for the last 8 months with fluticasone propionate (FP) >=500
mcg/day (or equivalent).

- Disease Severity: Subjects must be assessed as having life-threatening /serious
debilitating asthma in order to enroll, as defined by the following: Subjects enrolled
in MEA115588 must meet one of the following criteria: a) Subject has a history of at
least one intubation during their lifetime; b) >=3 asthma exacerbations in the 12
months prior to screening for MEA115588; c) >=1 or more hospitalization for asthma
exacerbation in the 12 months prior to screening for MEA115588. Subjects enrolled in
MEA115575 must meet one of the following criteria: d) Subject has a history of at
least one intubation during their lifetime; e) Their optimized dose at randomization
in MEA115575 was >=10mg of prednisone; f) >=1 or more hospitalization for asthma
exacerbation in the 12 months prior to screening for MEA115575.

- Clinical Benefit: Subjects must have experienced documented clinical benefit to
enroll. Subjects must meet the following criteria demonstrating clinical benefit:
Subjects enrolled in MEA115588 who received mepolizumab must meet all of the following
criteria: a) Subject must have had a reduction in their exacerbation frequency by
>=50% during MEA115588. The baseline for comparison is the total number of
exacerbations reported in the 12 months prior to screening for MEA115588. b) The
investigator response on the "Clinician-Rated Response to Therapy" questionnaire at
Visit 10 was either: mildly improved, moderately improved or significantly improved.
Subjects enrolled in MEA115588 who received placebo must meet all of the following
criteria: c) Subject must have had a reduction in their exacerbation frequency by
>=50% during the first 8 months of MEA115661. The baseline for comparison is the total
number of exacerbations reported in the 12 months prior to screening for MEA115588; d)
The investigator confirms that the subject demonstrated improvement during MEA115661.
Subjects enrolled in MEA115575 who received mepolizumab must meet all of the following
criteria: e) Subject must have reduced their oral corticosteroid dose by >=50% during
MEA115575. The baseline for comparison is the subject's optimized oral corticosteroid
(OCS) dose at randomization in MEA115575; f) The investigator response on the
"Clinician-Rated Response to Therapy" questionnaire at Visit 9 was either: mildly
improved, moderately improved or significantly improved. Subjects enrolled in
MEA115575 who received placebo must meet all of the following criteria: g) Subject
must have reduced their oral corticosteroid dose at randomization by >=50% in the
first 6 months of MEA115661. The baseline for comparison is the subject's optimized
OCS dose at randomization in MEA115575; h) The investigator confirms that the subject
demonstrated improvement during MEA115661.
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

- Health Status: Clinically significant change in health status during MEA115661 which
in the opinion of the investigator would make the subject unsuitable for participation
in this long-term study.

- Pregnancy: Subjects who are pregnant or breastfeeding. Subjects should not be enrolled
if they plan to become pregnanDeart during the time of study participation.

- Exacerbation History: Subjects who received placebo in MEA115588 and had NO
exacerbations during the study.

- Oral Corticosteroid Use: Subjects who received placebo in MEA115575 and were able to
discontinue oral corticosteroid therapy by the end of the study.

- Smoking Status: Current smokers

- Previous Significant Protocol Deviation: Subjects who were excluded from the per
protocol analysis due to significant protocol deviations in either study MEA115575 or
MEA115588.

- Electrocardiogram (ECG) Assessment: A clinically significant ECG abnormality at the
exit visit of MEA115661, as determined by the investigator.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/05/2014
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
5/10/2017
Sample size
Target
Accrual to date
Final
339
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - New Lambton
Recruitment hospital [2] 0 0
GSK Investigational Site - Bedford Park
Recruitment hospital [3] 0 0
GSK Investigational Site - Clayton
Recruitment hospital [4] 0 0
GSK Investigational Site - Nedlands
Recruitment postcode(s) [1] 0 0
2305 - New Lambton
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment postcode(s) [3] 0 0
3168 - Clayton
Recruitment postcode(s) [4] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Minnesota
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
North Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Ohio
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
Utah
Country [12] 0 0
Argentina
State/province [12] 0 0
Buenos Aires
Country [13] 0 0
Argentina
State/province [13] 0 0
Mendoza
Country [14] 0 0
Argentina
State/province [14] 0 0
Santa Fe
Country [15] 0 0
Belgium
State/province [15] 0 0
Bruxelles
Country [16] 0 0
Belgium
State/province [16] 0 0
Gent
Country [17] 0 0
Belgium
State/province [17] 0 0
Leuven
Country [18] 0 0
Belgium
State/province [18] 0 0
Liège
Country [19] 0 0
Canada
State/province [19] 0 0
Alberta
Country [20] 0 0
Canada
State/province [20] 0 0
British Columbia
Country [21] 0 0
Canada
State/province [21] 0 0
Manitoba
Country [22] 0 0
Canada
State/province [22] 0 0
Ontario
Country [23] 0 0
Canada
State/province [23] 0 0
Quebec
Country [24] 0 0
Chile
State/province [24] 0 0
Reg Del Libert Bern Ohiggins
Country [25] 0 0
Chile
State/province [25] 0 0
Santiago
Country [26] 0 0
Chile
State/province [26] 0 0
Talcahuano
Country [27] 0 0
Czechia
State/province [27] 0 0
Brno
Country [28] 0 0
Czechia
State/province [28] 0 0
Olomouc
Country [29] 0 0
Czechia
State/province [29] 0 0
Praha 4
Country [30] 0 0
Czechia
State/province [30] 0 0
Praha 8
Country [31] 0 0
France
State/province [31] 0 0
Gières
Country [32] 0 0
France
State/province [32] 0 0
Kremlin-Bicêtre
Country [33] 0 0
France
State/province [33] 0 0
Lille cedex
Country [34] 0 0
France
State/province [34] 0 0
Lyon cedex 04
Country [35] 0 0
France
State/province [35] 0 0
Marseille cedex 20
Country [36] 0 0
France
State/province [36] 0 0
Montpellier cedex 5
Country [37] 0 0
France
State/province [37] 0 0
Nantes cedex 1
Country [38] 0 0
France
State/province [38] 0 0
Paris Cedex 18
Country [39] 0 0
France
State/province [39] 0 0
Perpignan
Country [40] 0 0
France
State/province [40] 0 0
Strasbourg
Country [41] 0 0
Germany
State/province [41] 0 0
Bayern
Country [42] 0 0
Germany
State/province [42] 0 0
Brandenburg
Country [43] 0 0
Germany
State/province [43] 0 0
Hessen
Country [44] 0 0
Germany
State/province [44] 0 0
Niedersachsen
Country [45] 0 0
Germany
State/province [45] 0 0
Rheinland-Pfalz
Country [46] 0 0
Germany
State/province [46] 0 0
Schleswig-Holstein
Country [47] 0 0
Germany
State/province [47] 0 0
Berlin
Country [48] 0 0
Germany
State/province [48] 0 0
Hamburg
Country [49] 0 0
Germany
State/province [49] 0 0
Magdeburg
Country [50] 0 0
Italy
State/province [50] 0 0
Campania
Country [51] 0 0
Italy
State/province [51] 0 0
Emilia-Romagna
Country [52] 0 0
Italy
State/province [52] 0 0
Liguria
Country [53] 0 0
Italy
State/province [53] 0 0
Puglia
Country [54] 0 0
Italy
State/province [54] 0 0
Umbria
Country [55] 0 0
Italy
State/province [55] 0 0
Veneto
Country [56] 0 0
Japan
State/province [56] 0 0
Chiba
Country [57] 0 0
Japan
State/province [57] 0 0
Fukuoka
Country [58] 0 0
Japan
State/province [58] 0 0
Gunma
Country [59] 0 0
Japan
State/province [59] 0 0
Hokkaido
Country [60] 0 0
Japan
State/province [60] 0 0
Ibaraki
Country [61] 0 0
Japan
State/province [61] 0 0
Kanagawa
Country [62] 0 0
Japan
State/province [62] 0 0
Okinawa
Country [63] 0 0
Japan
State/province [63] 0 0
Osaka
Country [64] 0 0
Japan
State/province [64] 0 0
Tokyo
Country [65] 0 0
Korea, Republic of
State/province [65] 0 0
Anyang-Si Gyeonggi-do
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Bucheon city, Gyenggi-do
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Cheongju, Chungcheongbuk-do
Country [68] 0 0
Korea, Republic of
State/province [68] 0 0
Donggu Gwangju
Country [69] 0 0
Korea, Republic of
State/province [69] 0 0
Seoul
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Suwon-si, Gyeonggi-do
Country [71] 0 0
Netherlands
State/province [71] 0 0
Amsterdam
Country [72] 0 0
Netherlands
State/province [72] 0 0
Leeuwarden
Country [73] 0 0
Poland
State/province [73] 0 0
Bialystok
Country [74] 0 0
Poland
State/province [74] 0 0
Krakow
Country [75] 0 0
Russian Federation
State/province [75] 0 0
Chelyabinsk
Country [76] 0 0
Russian Federation
State/province [76] 0 0
Moscow
Country [77] 0 0
Russian Federation
State/province [77] 0 0
Saint-Petersburg
Country [78] 0 0
Russian Federation
State/province [78] 0 0
St. Petersburg
Country [79] 0 0
Spain
State/province [79] 0 0
Alicante
Country [80] 0 0
Spain
State/province [80] 0 0
Barcelona
Country [81] 0 0
Spain
State/province [81] 0 0
Pozuelo De Alarcón/Madrid
Country [82] 0 0
Ukraine
State/province [82] 0 0
Kharkiv
Country [83] 0 0
Ukraine
State/province [83] 0 0
Kiev
Country [84] 0 0
Ukraine
State/province [84] 0 0
Mykolaiv
Country [85] 0 0
Ukraine
State/province [85] 0 0
Vinnytsia
Country [86] 0 0
United Kingdom
State/province [86] 0 0
Leicestershire
Country [87] 0 0
United Kingdom
State/province [87] 0 0
Bradford
Country [88] 0 0
United Kingdom
State/province [88] 0 0
Plymouth
Country [89] 0 0
United Kingdom
State/province [89] 0 0
Southampton

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a multi-center, open-label, long-term study of subcutaneously (SC) administered
mepolizumab 100mg in addition to standard of care (SOC), in subjects with severe eosinophilic
asthma. This study will enroll a subset of subjects from Study MEA115661 who have
demonstrated clear benefit from therapy and who without continuation of mepolizumab therapy
are individuals at greatest risk of serious deterioration of their health status. In order to
target individuals at greatest risk for serious deterioration of their health status, only
subjects from the MEA115661 study with a history of life-threatening or seriously
debilitating asthma, will be allowed to participate. Subjects meeting all of the eligibility
criteria for the study will be offered the opportunity to consent for this study of up to 128
weeks in length (including the Follow-Up Visit). This study will give opportunity to extend
the collection of clinical data for long-term use and further assess the sustainability of
efficacy in a population likely to experience significant loss of asthma control and the need
for higher doses of systemic steroids if returned to SOC only.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02135692
Trial related presentations / publications
Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, Kato M, Albers FC, Bradford ES, Gilson MJ, Price RG, Humbert M. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clin Ther. 2019 Oct;41(10):2041-2056.e5. doi: 10.1016/j.clinthera.2019.07.007. Epub 2019 Aug 22.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries